Royal Fund Management, LLC Amgen Inc Transaction History

Royal Fund Management, LLC

$1.66 Billion
Q3 2024

A detailed history of Royal Fund Management, LLC transactions in Amgen Inc stock. As of the latest transaction made, Royal Fund Management, LLC holds 15,135 shares of AMGN stock, worth $3.99 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares

15,135

Previous 16,074 5.84%

Holding current value

$3.99 Million

Previous $5.02 Million 2.91%

% of portfolio

0.29%

Previous 0.53%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 08, 2024	SELL	$309.38 - $337.38 $290,507 - $316,799	-939 Reduced 5.84%	15,135 $4.88 Million
Q2 2024 Jul 18, 2024	SELL	$262.75 - $319.31 $342,626 - $416,380	-1,304 Reduced 7.5%	16,074 $5.02 Million
Q1 2024 Apr 11, 2024	BUY	$268.87 - $324.56 $783,487 - $945,767	2,914 Added 20.15%	17,378 $4.94 Million
Q4 2023 Feb 06, 2024	SELL	$255.7 - $288.46 $171,063 - $192,979	-669 Reduced 4.42%	14,464 $4.17 Million
Q3 2023 Oct 17, 2023	SELL	$218.65 - $271.46 $46,353 - $57,549	-212 Reduced 1.38%	15,133 $4.07 Million
Q2 2023 Jul 12, 2023	SELL	$214.27 - $253.37 $978,999 - $1.16 Million	-4,569 Reduced 22.94%	15,345 $3.41 Million
Q1 2023 Apr 10, 2023	BUY	$225.79 - $275.2 $8,354 - $10,182	37 Added 0.19%	19,914 $4.81 Million
Q4 2022 Jan 20, 2023	BUY	$229.03 - $291.01 $69,854 - $88,758	305 Added 1.56%	19,877 $0
Q3 2022 Nov 14, 2022	BUY	$224.46 - $253.15 $26,261 - $29,618	117 Added 0.6%	19,572 $4.41 Million
Q2 2022 Jul 28, 2022	BUY	$230.71 - $256.74 $149,961 - $166,881	650 Added 3.46%	19,455 $4.73 Million
Q1 2022 May 13, 2022	SELL	$219.27 - $242.57 $101,522 - $112,309	-463 Reduced 2.4%	18,805 $4.55 Million
Q4 2021 Feb 11, 2022	BUY	$198.88 - $227.6 $1.23 Million - $1.41 Million	6,177 Added 47.19%	19,268 $4.33 Million
Q3 2021 Oct 20, 2021	BUY	$212.27 - $248.7 $244,959 - $286,999	1,154 Added 9.67%	13,091 $2.78 Million
Q2 2021 Jul 26, 2021	SELL	$233.58 - $259.14 $1.38 Million - $1.53 Million	-5,902 Reduced 33.08%	11,937 $2.91 Million
Q1 2021 Apr 29, 2021	BUY	$221.91 - $258.6 $645,092 - $751,750	2,907 Added 19.47%	17,839 $4.44 Million
Q4 2020 Feb 02, 2021	SELL	$216.38 - $257.67 $794,980 - $946,679	-3,674 Reduced 19.75%	14,932 $3.43 Million
Q3 2020 Oct 13, 2020	SELL	$234.65 - $260.95 $4,927 - $5,479	-21 Reduced 0.11%	18,606 $4.73 Million
Q2 2020 Aug 06, 2020	BUY	$197.81 - $242.74 $537,251 - $659,281	2,716 Added 17.07%	18,627 $4.39 Million
Q1 2020 May 08, 2020	SELL	$182.24 - $241.7 $1.83 Million - $2.43 Million	-10,058 Reduced 38.73%	15,911 $3.23 Million
Q4 2019 May 11, 2020	BUY	$189.21 - $243.2 $374,446 - $481,292	1,979 Added 8.25%	25,969 $6.26 Million
Q3 2019 May 08, 2020	BUY	$174.11 - $208.62 $229,476 - $274,961	1,318 Added 5.81%	23,990 $4.64 Million
Q2 2019 May 08, 2020	SELL	$166.7 - $195.41 $2.47 Million - $2.9 Million	-14,821 Reduced 39.53%	22,672 $4.18 Million
Q1 2019 May 11, 2020	BUY	$180.87 - $203.88 $109,607 - $123,551	606 Added 1.64%	37,493 $7.12 Million
Q4 2018 May 07, 2020	SELL	$178.4 - $208.25 $176,616 - $206,167	-990 Reduced 2.61%	36,887 $7.18 Million
Q3 2018 May 07, 2020	SELL	$185.29 - $208.89 $58,922 - $66,427	-318 Reduced 0.83%	37,877 $7.85 Million
Q2 2018 May 07, 2020	SELL	$166.05 - $186.51 $116,733 - $131,116	-703 Reduced 1.81%	38,195 $7.05 Million
Q1 2018 May 07, 2020	BUY	$169.43 - $198.0 $6.59 Million - $7.7 Million	38,880 Added 216000.0%	38,898 $6.63 Million
Q4 2017 May 07, 2020	BUY	$168.79 - $188.59 $3,038 - $3,394	18 New	18 $3,000
Q3 2017 May 07, 2020	SELL	$167.29 - $191.0 $21,747 - $24,830	-130 Closed	0 $0
Q2 2017 May 07, 2020	BUY	N/A	130	130 $22,000

Others Institutions Holding AMGN

# of Institutions

3,125

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $141B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Royal Fund Management, LLC with notifications on news.

Account

Royal Fund Management, LLC Amgen Inc Transaction History